News

News and Press Releases
About the CF Foundation | Our Research Approach | Research Cystic Fibrosis Foundation Launches $500 Million Path to a Cure

Nonprofit issues challenge to accelerate treatments for every person with CF

| 5 min read
Research | CFTR Modulators Cystic Fibrosis Foundation Is Exploring New CFTR Modulators

The Cystic Fibrosis Foundation announced today that it has licensed a compound to the biopharmaceutical company AbbVie to develop into a potential CFTR modulator treatment.

| 2 min read
Research | CFTR Modulators | Drug Pipeline CF Foundation Celebrates FDA Approval of Triple Combination

The U.S. Food and Drug Administration has approved the use of the triple-combination modulator elexacaftor/tezacaftor/ivacaftor (Trikafta™) for people with cystic fibrosis ages 12 and older who have at least one copy of the F508del mutation.

| 3 min read
Research | CFTR Modulators | Drug Pipeline Cystic Fibrosis Foundation statement on FDA approval of TRIKAFTA, the first triple combination therapy for the most common CF mutation

This medicine represents the single greatest therapeutic advancement in the history of CF, offering a treatment for the underlying cause of the disease that could eventually benefit more than 90 percent of people with CF.  

| 3 min read
Research Enterprise Therapeutics Awarded Up to $7M to Develop Mucus-Clearance Drug for People With CF

The Cystic Fibrosis Foundation has awarded up to $7 million to Enterprise Therapeutics to develop a compound that targets a non-CFTR chloride channel in lung cells. If successful, the drug could help mucus become more hydrated and easier to clear from the lungs of all people with CF, regardless of their CFTR mutations.

| 2 min read